Monitoring system for isolated limb perfusion based on a portable gamma camera

Summary

Background: The treatment of malignant melanoma or sarcomas on a limb using extremity perfusion with tumour necrosis factor (TNF-α) and melphalan can result in a high degree of systemic toxicity if there is any leakage from the isolated blood territory of the limb into the systemic vascular territory. Leakage is currently controlled by using radiotracers and heavy external probes in a procedure that requires continuous manual calculations. The aim of this work was to develop a light, easily transportable system to monitor limb perfusion leakage by controlling systemic blood pool radioactivity with a portable gamma camera adapted for intraoperative use as an external probe, and to initiate its application in the treatment of MM patients. Methods: A special collimator was built for maximal sensitivity. Software for acquisition and data processing in real time was developed. After testing the adequacy of the system, it was used to monitor limb perfusion leakage in 16 patients with malignant melanoma to be treated with perfusion of TNF-α and melphalan. Results: The field of view of the detector system was 13.8 cm, which is appropriate for the monitoring, since the area to be controlled was the precordial zone. The sensitivity of the system was 257 cps/MBq. When the percentage of leakage reaches 10% the associated absolute error is ± 1%. After a mean follow-up period of 12 months, no patients have shown any significant or lasting side-effects. Partial or complete remission of lesions was seen in 9 out of 16 patients (56%) after HILP with TNF-α and melphalan. Conclusion: The detector system together with specially developed software provides a suitable automatic continuous monitoring system of any leakage that may occur during limb perfusion. This technique has been successfully implemented in patients for whom perfusion with TNF-α and melphalan has been indicated.

Zusammenfassung

Hintergrund: Bei der Behandlung maligner Melanome oder Sarkome der Gliedmaßen mit Extremitätenperfusion mit Tumor-Nekrose-Faktor- alpha (TNF-α) und Melphalan kann deren Austritt aus dem isolierten Gefäßbett in den systemischen Kreislauf eine ausgeprägte Toxizität verursachen. Zurzeit erfolgt die Leckage-Kontrolle mit Radiotracern und schweren externen Messgeräten in einem Verfahren, das ständige manuelle Berechnungen erfordert. Das Ziel dieser Arbeit war, die Entwicklung eines leichten, einfach zu transportierenden Systems zum Leckage-Monitoring bei Extremitätenperfusion, wobei die Radioaktivität des systemischen Blutpools mit einer transportablen Gamma-Kamera, adaptiert als externes Messgerät für das intraoperative Monitoring, kontrolliert wird. Ziel war auch, die Anwendung dieses Systems bei MM-Patienten einzuführen. Methoden: Für maximale Sensitivität wurde eine spezielle Blende konstruiert. Für die Datenerfassung und -verarbeitung in Echtzeit wurde eine Software entwickelt. Nach einem Eignungstest wurde das System bei 16 MM-Patienten, die eine Extremitätenperfusion mit TNF-α und Melphalan erhalten sollten, zum Leckage-Monitoring eingesetzt. Ergebnisse: Das Beobachtungsfeld des Detektorsystems war mit 13,8 cm angemessen für das Monitoring des präkordialen Kontrollbereichs. Die Sensitivität des Systems betrug 257 cps/MBq. Wenn der Leckageanteil 10% erreicht, liegt der absolute Fehler bei ± 1%. Nach einer mittleren Nachbeobachtungszeit von 12 Monaten zeigte kein Patient signifikante oder bleibende Nebenwirkungen. Partielle oder vollständige Remissionen der Läsionen wurden nach HILP mit TNF-α und Melphalan bei 9 von 16 Patienten (56%) beobachtet. Schlussfolgerung: Das Detektorsystem mit der speziell entwickelten Software, eignet sich zur automatischen, kontinuierlichen überwachung von Leckagen während der Extremitätenperfusion. Es wurde erfolgreich bei Patienten eingesetzt, bei denen die Perfusion mit TNF-α und Melphalan indiziert war.

Keywords

Limb perfusion - tumour necrosis factor alfa - melphalan - radiotracer - gamma camera - leakage monitoring

Schlüsselwörter

Extremitätenperfusion - Tumor-Nekrose-Faktoralpha - Melphalan - Radiotracer - Gamma-Kamera - Leckage-Monitoring

Publikationsverlauf

Eingereicht: 29. Oktober 2008

Angenommen: 05. Mai 2009

Publikationsdatum:
22. Januar 2018 (online)

• References

• 1 Armas F, Intra M, Vega V. et al. Radioguided surgery of non-palpable breast lesions. Rev Esp Med Nucl 2007; 26: 107-120.
• 2 Brobeil A, Berman C, Cruse CW. et al. Efficacy of hyperthermic isolated limb perfusion for extremity- confined recurrent melanoma. Ann Surg Oncol 1998; 5: 376-383.
• 3 Casara D, Rubello D, Pilati P. et al. Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and ^99mTc-HSA. Nucl Med Commun 2004; 25: 61-66.
• 4 Cavaliere R, Ciocatto E, Giovanella B. Selective heat sensitivity of cancer cells :Biochemical and clinical studies. Cancer 1967; 20: 1351-1381.
• 5 Cherix S, Speiser M, Matter M. et al. Isolated limb perfusion with tumor necrosis factor and melpha- lan for non-resectable soft tissue sarcomas: Long term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol 2008; 98: 148-155.
• 6 Comett WR, McCall LM, Petersen RP. et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24: 4196-4201.
• 7 Creech O, Ryan R, Krementz E. Treatment of malignant melanoma by isolation perfusion technique. JAMA 1956; 169: 339-343.
• 8 De Wilt JH, ten Hagen TL, de Boeck G. et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 1000-1003.
• 9 Eggermont AM, Schraffordt KH, Lienard D. et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon- gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14: 2653-2665.
• 10 Eggermont AM, Schraffordt KH, Klausner JM. et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756-764.
• 11 Feldman AL, Alexander Jr HR, Bartlett DL. et al. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 1999; 6: 562-567.
• 12 Fernández MM, Benlloch JM, Cerdá J. et al. A flat-panel-based mini gamma camera for lymph nodes studies. Nucl Instrum Methods Phys Res A 2004; 527: 92-96.
• 13 Grünhagen DJ, de Wilt JHW, ten Hagen TLM, Eggermont AEE. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nature Clin Pract Oncol 2006; 3: 94-103.
• 14 Hoekstra HJ. The European approach to in-transit melanoma lesions. Int J Hyperthermia 2008; 24: 227-237.
• 15 Knoll GF. Radiation Detection and Measurement. New York: Wiley; 2000: 119-124.
• 16 Kroon BBR, Fraker DL, Vrouenraets BC, Thompson JF. Isolated limb perfusion: results and complications. In: Thompson JF, Morton DL, Kroon BB. Textbook of Melanoma. London: Martin Dunitz; 2004: 410-428.
• 17 Lejeune F, Lienard D, Eggermont A. et al. Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience. Bull Cancer 1995; 82: 561-567.
• 18 Lienard D, Eggermont AM, Koops HS. et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9: 491-502.
• 19 Lindner P, Fjalling M, Hafstrom L. et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Eur J Surg Oncol 1999; 25: 179-185.
• 20 Luck J. Action of P-did(2chloroetylo)-amino- L-phenylalanine on Hearding Passey mouse melanoma. Science 1956; 123: 984-985.
• 21 Nooijen PI, Eggermont MVI, Schalkwijk L. et al. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern. Cancer Res 1998; 58: 4880-4887.
• 22 Sánchez F, Fernández MM, Giménez M. et al. Performance tests of two portable mini gamma cameras for medical applications. Med Phys 2006; 33: 4210-4220.
• 23 Sekiya H, Hattori K, Kubo H. et al. Studies of the performance of different front-end systems for flat- panel multi-anode PMTs with CsI(Tl) scintillator arrays. Nucl Instr and Meth A 2006; 563: 49-53.
• 24 Stam TC, Swaak AJ, de Vries MR. et al. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol 2000; 7: 268-275.
• 25 Stehlin J. Hyperthermic perfusion with chemotherapy for cancers extremities. Surg Gynecol Oncol 1969; 129: 305-308.
• 26 Thompson JF, Gianoutsos P. Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 16: 227-233.
• 27 Vrouenraets BC, Hart GA, Eggermont AM. et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 1999; 88: 522-530.
• 28 Vrouenraets BC, Eggermont AM, Hart AA. et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. Eur J Surg Oncol 2001; 27: 390-395.
• 29 Zwaveling JH, Maring JK, Mulder AB. et al. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system. Cancer Res 1996; 56: 3948-3953.
• 30 Zwaveling JH, Maring JK, Clarke FL. et al. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. Cnt Care Med 1996; 24: 765-770.